MiRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer

Expert Review of Respiratory Medicine

Volumn 5, Issue 5, 2011, Pages 699-709

  Gao, Wen ^a   Xu, Jing ^a   Shu, Yong Qian ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

diagnosis; miRNAs; NSCLC; prevention

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 145; MICRORNA 15; MICRORNA 155; MICRORNA 16; MICRORNA 21; MICRORNA 218; MICRORNA 31; MICRORNA 34; MICRORNA LET 7; UNCLASSIFIED DRUG;

APOPTOSIS; BODY FLUID; CANCER DIAGNOSIS; CANCER PREVENTION; CELL GROWTH; DISEASE COURSE; GENETIC VARIABILITY; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; PATHOGENESIS; PROGNOSIS; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 80053362056     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.55     Document Type: Review

References (100)

1. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5(11), 845-856 (2005 (Pubitemid 41746029)
2. Bartel DP. MicroRNAs: genomics biogenesis, mechanism, and function. Cell 116(2), 281-297 (2004
3. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113(6), 673-676 (2003 (Pubitemid 36724931)
4. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6(11), 857-866 (2006 (Pubitemid 44629897)
5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1), 15-20 (2005 (Pubitemid 40094598)
6. Brennecke J, Stark A, Russell RB et al. Principles of microRNA-target recognition.PLoS Biol. 3(3), e85 (2005
7. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 99(24), 15524-15529 (2002 (Pubitemid 35403967)
8. Cimmino A, Calin GA, Fabbri M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 102(39), 13944-13949 (2005 (Pubitemid 41377683)
9. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435 (7043), 834-838 (2005 (Pubitemid 40839735)
10. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 103(7), 2257-2261 (2006 (Pubitemid 43271657)
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000 (Pubitemid 30046295)
12. Ota A, Tagawa H, Karnan S et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 64(9), 3087-3095 (2004 (Pubitemid 38581408)
13. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 133(2), 217-222 (2008
14. He L, He X, Lim LP et al. A microRNA component of the p53 tumour suppressor network. Nature 447 (7148), 1130-1134 (2007 (Pubitemid 47014436)
15. Gallardo E, Navarro A, Violas N et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30(11), 1903-1909 (2009
16. Chang TC, Wentzel EA, Kent OA et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26(5), 745-752 (2007 (Pubitemid 46856245)
17. Tarasov V, Jung P, Verdoodt B et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6(13), 1586-1593 (2007) (Pubitemid 47327945)
18. Bommer GT, Gerin I, Feng Y et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17(15), 1298-1307 (2007 (Pubitemid 47176893)
19. Trang P, Wiggins JF, Daige CL et al. Systemic delivery of tumor suppressor microrna mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19(6), 1116-1122 (2011
20. Wiggins JF, Ruffino L, Kelnar K et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 70(14), 5923-5930 (2010
21. Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64(11), 3753-3756 (2004 (Pubitemid 38697282)
22. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell 120(5), 635-647 (2005 (Pubitemid 40343076)
23. Kumar MS, Erkeland SJ, Pester RE et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. USA 105(10), 3903-3908 (2008 (Pubitemid 351723497)
24. Esquela-Kerscher A, Trang P, Wiggins JF et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7(6), 759-764 (2008 (Pubitemid 351520040)
25. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21(9), 1025-1030 (2007 (Pubitemid 46686471)
26. Trang P, Medina PP, Wiggins JF et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 29(11), 1580-1587 (2010
27. Davidson MR, Larsen JE, Yang IA et al. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One 5(9), e12560 (2010
28. Wu DW, Cheng YW, Wang J et al. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res. 70(24), 10392-10401 (2010
29. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3), 189-198 (2006 (Pubitemid 43357945)
30. Chen Z, Zeng H, Guo Y et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J. Exp. Clin. Cancer Res. 29, 151 (2010
31. Cho WC, Chow AS, Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur. J. Cancer 45, 2197-2206 (2009
32. Bandi N, Zbinden S, Gugger M et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or downregulated in non-small cell lung cancer. Cancer Res. 69(13), 5553-5559 (2009
33. Navarro A, Diaz T, Gallardo E et al. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. J. Surg. Oncol. 103(5), 411-415 (2011
34. Metzler M, Wilda M, Busch K et al. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 39(2), 167-169 (2004 (Pubitemid 38056091)
35. Eis PS, Tam W, Sun L et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. USA 102(10), 3627-3632 (2005 (Pubitemid 40354662)
36. Donnem T, Eklo K, Berg T et al. Prognostic impact of miR-155 in non-small cell lung cancer evaluated by in situ hybridization. J. Transl. Med. 9, 6 (2011
37. Kong W, Yang H, He L et al. MicroRNA-155 is regulated by the transforming growth factor b/SMAD pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell Biol. 28(22), 6773-6784 (2008
38. Raponi M, Dossey L, Jatkoe T et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 69(14), 5776-5783 (2009
39. Markou A, Tsaroucha EG, Kaklamanis L et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem. 54(10), 1696-1704 (2008
40. Patnaik SK, Kannisto E, Knudsen S et al. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 70(1), 36-45 (2010
41. Frezzetti D, Menna MD, Zoppoli P et al. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 30(3), 275-286 (2011
42. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18(3), 282-293 (2010
43. Seike M, Goto A, Okano T et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl. Acad. Sci. USA 106(29), 12085-12090 (2009
44. Lu Z, Liu M, Stribinskis V et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27(31), 4373-4379 (2008 (Pubitemid 352010003)
45. Zhang JG, Wang JJ, Zhao F et al. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin. Chim. Acta 411(11-12), 846-852 (2010
46. Gao W, Yu Y, Cao H et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed. Pharmacother. 64(6), 399-408 (2010
47. Markou A, Tsaroucha EG, Kaklamanis L et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem. 54(10), 1696-1704 (2008
48. Liu X, Sempere LF, Ouyang H et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Invest. 120(4), 1298-1309 (2010
49. Hu Z, Chen J, Tian T et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J. Clin. Invest. 118(7), 2600-2608 (2008 (Pubitemid 351949787)
50. Chin LJ, Ratner E, Leng S et al. A SNP in a let-7 microRNA complementary site in the KRAS 3 untranslated region increases non-small cell lung cancer risk. Cancer Res. 68(20), 8535-8540 (2008
51. Lim LP, Lau NC, Garrett-Engele P et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433 (7027), 769-773 (2005 (Pubitemid 40292988)
52. Tang F, Hajkova P, Barton SC et al. MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res. 34(2), e9 (2006
53. Goswami RS, Waldron L, Machado J et al. Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffinembedded samples. BMC Biotechnol. 10, 47 (2010
54. Varadhachary GR, Spector Y, Abbruzzese JL et al. Prospective gene signature study using microrna to identify the tissue of origin in patients with carcinoma of unknown primary (CUP). Clin. Cancer Res. 17(12), 4063-70 (2011
55. Rosenfeld N, Aharonov R, Meiri E et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 26(4), 462-469 (2008 (Pubitemid 351501813)
56. Mueller WC, Spector Y, Edmonston TB et al. Accurate classification of metastatic brain tumors using a novel microRNAbased test. Oncologist 16(2), 165-174 (2011
57. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc. Natl. Acad. Sci. USA 105(30), 10513-10518 (2008
58. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008
59. Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 28(10), 1721-1726 (2010
60. Foss KM, Sima C, Ugolini D et al. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J. Thorac. Oncol. 6(3), 482-488 (2011
61. Keller A, Leidinger P, Borries A et al. miRNAs in lung cancer - studying complex fingerprints in patients blood cells by microarray experiments. BMC Cancer 9, 353 (2009
62. Rabinowits G, Gerel-Taylor C, Day JM et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung. Cancer 10(1), 42-46 (2009
63. Boeri M, Verri C, Conte D et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl. Acad. Sci. USA 108(9), 3713-3718 (2011
64. Park NJ, Zhou H, Elashoff D et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 15(17), 5473-5477 (2009
65. Hanke M, Hoefig K, Merz H et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 28(6), 655-661 (2010
66. Xie Y, Todd NW, Liu Z et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 67(2), 170-176 (2010
67. Yu L, Todd NW, Xing L et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 127(12), 2870-2878 (2010)
68. Xing L, Todd NW, Yu L et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod. Pathol. 23(8), 1157-1164 (2010
69. Lebanony D, Benjamin H, Gilad S et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J. Clin. Oncol. 27(12), 2030-2037 (2009
70. Bishop JA, Benjamin H, Cholakh H et al. Accurate classification of non-small cell lung carcinoma using a novel microRNAbased approach. Clin. Cancer Res. 16(2), 610-619 (2010
71. Landi MT, Zhao Y, Rotunno M et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 16(2), 430-441 (2010
72. Garfield DH, Cadranel J, West HL. Bronchioloalveolar carcinoma: the case for two diseases. Clin. Lung. Cancer 9(1), 24-29 (2008 (Pubitemid 351251597)
73. Maeshima A, Sakamoto M, Hirohashi S. Mixed mucinous-type and non-mucinoustype adenocarcinoma of the lung: immunohistochemical examination and K-ras gene mutation. Virchows Arch. 440(6), 598-603 (2002 (Pubitemid 34809691)
74. Inamura K, Togashi Y, Nomura K et al. Let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a noninvasive carcinoma, and is not correlated with prognosis. Lung Cancer 58(3), 392-396 (2007 (Pubitemid 350051514)
75. Dacic S, Kelly L, Shuai Y et al. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod. Pathol. 23(12), 1577-1582 (2010
76. Fontana RS, Sanderson DR, Woolner LB et al. Lung cancer screening: the Mayo program. J. Occup. Med. 28(8), 746-750 (1986
77. Bach PB, Jett JR, Pastorino U et al. Computed tomography screening and lung cancer outcomes. JAMA 297(9), 953-961 (2007 (Pubitemid 46376749)
78. Infante M, Cavuto S, Lutman FR et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am. J. Respir. Crit. Care Med. 80(5), 445-453 (2009
79. Pastorino U. Lung cancer screening. Br. J. Cancer 102(12), 1681-1686 (2010
80. Henschke CI, McCauley DI, Yankelevitz DF et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet 354 (9173), 99-105 (1999 (Pubitemid 29313143)
81. Henschke CI, Shaham D, Yankelevitz DF et al. CT screening for lung cancer: past and ongoing studies. Semin. Thorac. Cardiovasc. Surg. 17(2), 99-106 (2005 (Pubitemid 41122295)
82. Henschke CI, Yankelevitz DF, Libby DM et al. Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med. 355(17), 1763-1771 (2006 (Pubitemid 44631359)
83. Wang XC, Du LQ, Tian LL et al. Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer 72(1), 92-99 (2011)
84. Arora H, Qureshi R, Jin S et al. miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1. Exp. Mol. Med. 43(5), 298-304 (2011)
85. Oh JS, Kim JJ, Byun JY et al. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int. J. Radiat. Oncol. Biol. Phys. 76(1), 5-8 (2010
86. Wei J, Liu LK, Gao W et al. Reduction of plasma microRNA-21 is associated with chemotherapeutic response in patients with non-small cell lung cancer. Chin. J. Cancer Res. 23, 123-128 (2011)
87. Zhu W, Shan X, Wang T et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J. Cancer 127(11), 2520-2529 (2010
88. Galluzzi L, Morselli E, Vitale I et al. miR-181a and miR-630 regulate cisplatininduced cancer cell death. Cancer Res. 70(5), 1793-1803 (2010)
89. Holleman A, Chung I, Olsen RR, et al. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene DOI:10.1038 (2011) (Epub ahead of print
90. Zhong M, Ma X, Sun C et al. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem. Biol. Interact. 184(3), 431-438 (2010
91. Garofalo M, Di Leva G, Romano G et al. miR-221 & 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16(6), 498-509 (2009)
92. Sun F, Fu H, Liu Q et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 582, 1564-1568 (2008
93. Sampson VB, Rong, NH, Han J et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 67, 9762-9770 (2007 (Pubitemid 47621223)
94. Du L, Schageman JJ, Subauste MC et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol. Cancer Res. 7, 1234-1243 (2009
95. Talotta F, Cimmino A, Matarazzo MR et al. An autoregulatory loopmediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 28, 73-84 (2009
96. Zhu S, Si ML, Wu H et al. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 282, 14328-14336 (2007 (Pubitemid 47100416)
97. Heegaard NH, Schetter AJ, Welsh JA et al. Circulating microRNA expression profiles in early stage non-small cell lung cancer. Int. J. Cancer. DOI: 10.1002 (2011) (Epub ahead of print
98. Xie L, Chen X, Wang L et al. Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer 10,591 (2010
99. Keller A, Leidinger P, Gislefoss R et al. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol. 8(3), 506-516 (2011
100. Shen J, Todd NW, Zhang H et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab. Invest. 91, 579-587 (2011